Valuation: Daxor Corporation

Market Cap 49.51M 44.98M 41.56M 37.54M 70.84M 4.65B 73.33M 500M 198M 2.49B 186M 182M 7.9B P/E 2026 *
-40.4x
P/E 2027 * -283x
Enterprise Value 49.51M 44.98M 41.56M 37.54M 70.84M 4.65B 73.33M 500M 198M 2.49B 186M 182M 7.9B EV / Sales 2026 *
5.32x
EV / Sales 2027 * 3.02x
Free-Float
46.7%
Yield 2026 *
-
Yield 2027 * -
1 day+0.24%
1 week+0.36%
Current month-7.83%
1 month-16.86%
3 months-18.46%
6 months-21.12%
Current year-42.51%
1 week 8.24
Extreme 8.24
8.72
1 month 8.24
Extreme 8.24
10.12
Current year 8.24
Extreme 8.24
14.75
1 year 8.24
Extreme 8.24
14.76
3 years 6.55
Extreme 6.55
14.76
5 years 6.55
Extreme 6.55
14.76
10 years 3.4
Extreme 3.4001
24.08
Manager TitleAgeSince
Chief Executive Officer 56 01/01/2013
Director of Finance/CFO 69 28/09/2018
Chief Tech/Sci/R&D Officer - 05/06/2024
Director TitleAgeSince
Director/Board Member 91 01/01/1989
Chairman 56 14/02/2017
Director/Board Member 70 22/06/2016
Date Insider Type Main position Quantity % Market Cap. Importance
8/28/26 A Free

Chief Technology Officer

2,451 0.0420%
6/23/26 A Free

Director

2,500 0.0429%
4/8/26 A Buy

Chief Executive Officer

1,000 0.0172%
Change 5-day change 1-year change 3-year change Capi.($)
+0.24%+0.36%-34.77%+16.74% 49.51M
-0.75%-7.06%-5.37%+87.98% 14.23B
-4.37%-12.77%-8.77%+86.99% 9.6B
0.00%+1.71%-15.19%+28.33% 9.06B
-1.19%-6.88%-20.55%-19.55% 6.79B
-1.90%-8.88%-5.89%+94.40% 6.46B
-1.83%-3.31%+3.46%-0.27% 6.33B
-0.61%+2.78%+12.74%+23.33% 4.99B
-0.40%-0.88%+0.60%+11.26% 3.81B
-2.14%-1.61% - - 3.69B
Average -1.06%-1.70%-8.19%+36.58% 7B
Weighted average by Cap. -1.27%-2.31%-6.35%+48.58%

Financials

2026 *2027 *
Net sales 9.3M 8.45M 7.81M 7.05M 13.31M 873M 13.78M 93.88M 37.2M 469M 34.9M 34.16M 1.48B 16.4M 14.9M 13.77M 12.43M 23.47M 1.54B 24.29M 166M 65.6M 826M 61.54M 60.24M 2.62B
Net income -1.2M -1.09M -1.01M -910K -1.72M -113M -1.78M -12.11M -4.8M -60.47M -4.5M -4.41M -192M -200K -182K -168K -152K -286K -18.78M -296K -2.02M -800K -10.08M -750K -735K -31.92M
Net Debt - -
Projected Income Statement - Annual - Daxor Corporation
Logo Daxor Corporation
Daxor Corporation is a diversified, closed-end management investment company. Its focus and operations are as a medical device manufacturing, company. It specializes in blood volume measurement technology focused on blood volume testing innovation. It markets the Blood Volume Analyzer (BVA)-100, the diagnostic blood test cleared by the FDA to provide objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000 tests have been performed at hospital centers across the United States, enhancing hospital performance metrics in a range of surgical and medical conditions, including reducing mortality and readmissions in heart failure and critical care. Its facility provides on-demand, next day blood volume analysis results. It has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the United States Department of Defense.
Employees
45
Date Price Change Volume
13/11/26 $8.480 +0.24% 16,805
12/11/26 $8.460 -0.70% 5,715
11/11/26 $8.520 -0.12% 3,586
10/11/26 $8.530 -2.18% 6,128
09/11/26 $8.720 +3.20% 6,781
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
8.480USD
Average target price
20.00USD
Spread / Average Target
+135.85%